Carlos E Rodriguez-Martinez1,2, Gustavo Nino3, Jose A Castro-Rodriguez4. 1. Department of Pediatrics, School of Medicine, Universidad Nacional de Colombia, Bogota, Colombia. 2. Research Unit, Military Hospital of Colombia, Bogota, Colombia. 3. Division of Pediatric Pulmonary, Sleep Medicine and Integrative Systems Biology, Center for Genetic Research, Children's National Medical Center, George Washington University, Washington, District of Columbia. 4. Department of Pediatrics and Family Medicine, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Abstract
INTRODUCTION: Despite the many benefits that have been demonstrated by the continuous administration of inhaled corticosteroids (ICS) in persistent asthma, a new strategy for mild-asthma is emerging, consisting of using intermittent or as-needed ICS treatment in conjunction with short-acting beta2 agonists in response to symptoms. However, no previous studies have reported an economic evaluation comparing these two therapeutic strategies. METHODS: A Markov-type model was developed in order to estimate costs and health outcomes of a simulated cohort of pediatric patients with persistent asthma treated over a 12-month period. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from official databases provided by the Colombian Ministry of Health. The main outcome was the variable "quality-adjusted life-years" (QALYs). RESULTS: For the base-case analysis, the model showed that compared to intermittent ICS, daily therapy with ICS had lower costs (US$437.02 vs. 585.03 and US$704.62 vs. 749.81 average cost per patient over 12 months for school children and preschoolers, respectively), and the greatest gain in QALYs (0.9629 vs. 0.9392 QALYs and 0.9238 vs. 0.9130 QALYS for school children and preschoolers, respectively), resulting in daily therapy being considered dominant. CONCLUSIONS: The present analysis shows that compared to intermittent therapy, daily therapy with ICS for treating pediatric patients with recurrent wheezing and mild persistent asthma is a dominant strategy (more cost effective), because it showed a greater gain in QALYs with lower total treatment costs.
INTRODUCTION: Despite the many benefits that have been demonstrated by the continuous administration of inhaled corticosteroids (ICS) in persistent asthma, a new strategy for mild-asthma is emerging, consisting of using intermittent or as-needed ICS treatment in conjunction with short-acting beta2 agonists in response to symptoms. However, no previous studies have reported an economic evaluation comparing these two therapeutic strategies. METHODS: A Markov-type model was developed in order to estimate costs and health outcomes of a simulated cohort of pediatric patients with persistent asthma treated over a 12-month period. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from official databases provided by the Colombian Ministry of Health. The main outcome was the variable "quality-adjusted life-years" (QALYs). RESULTS: For the base-case analysis, the model showed that compared to intermittent ICS, daily therapy with ICS had lower costs (US$437.02 vs. 585.03 and US$704.62 vs. 749.81 average cost per patient over 12 months for school children and preschoolers, respectively), and the greatest gain in QALYs (0.9629 vs. 0.9392 QALYs and 0.9238 vs. 0.9130 QALYS for school children and preschoolers, respectively), resulting in daily therapy being considered dominant. CONCLUSIONS: The present analysis shows that compared to intermittent therapy, daily therapy with ICS for treating pediatric patients with recurrent wheezing and mild persistent asthma is a dominant strategy (more cost effective), because it showed a greater gain in QALYs with lower total treatment costs.
Authors: T Haahtela; M Järvinen; T Kava; K Kiviranta; S Koskinen; K Lehtonen; K Nikander; T Persson; K Reinikainen; O Selroos Journal: N Engl J Med Date: 1991-08-08 Impact factor: 91.245
Authors: Chiun-Fang Chiou; Marcia R Weaver; Michelle A Bell; Todd A Lee; James W Krieger Journal: Int J Qual Health Care Date: 2005-02 Impact factor: 2.038
Authors: William W Busse; Søren Pedersen; Romain A Pauwels; Wan C Tan; Yu-Zhi Chen; Carl Johan Lamm; Paul M O'Byrne Journal: J Allergy Clin Immunol Date: 2008-04-11 Impact factor: 10.793
Authors: M Turpeinen; K Nikander; A S Pelkonen; P Syvänen; R Sorva; H Raitio; P Malmberg; K Juntunen-Backman; T Haahtela Journal: Arch Dis Child Date: 2007-07-18 Impact factor: 3.791
Authors: Hai Thanh Phan; Giap Van Vu; Giang Thu Vu; Giang Hai Ha; Hai Quang Pham; Carl A Latkin; Bach Xuan Tran; Cyrus S H Ho; Roger C M Ho Journal: Int J Environ Res Public Health Date: 2020-05-19 Impact factor: 3.390